NKTR News and Press, Nektar Therapeutics From 05/11/22

Shares of Cue Biopharma have tumbled some 75% since November 2021, as somewhat underwhelming data from slowly developing Phase 1 trials are at fault. The company’s Immuno-STAT platform is a novel approach to immuno-oncology that should reduce risks associated with systemic expo...

Buying Penny Stocks on May 11th? Here’s What You Need to Know With another day of trading penny stocks and blue chips done, there is a lot for investors to consider. As we enter more selling off in the stock market, most traders are fearful right now about what the future could h...

Nektar Therapeutics press release (NASDAQ:NKTR): Q1 GAAP EPS of -$0.49 beats by $0.21. Revenue of $24.8M (+4.9% Y/Y) misses by $0.09M. Cash and investments in marketable securities at March 31, 2022 were approximately $704.4 million as compared to $798.8 million at&#x...

Nektar Therapeutics Reports First Quarter 2022 Financial Results PR Newswire SAN FRANCISCO , May 5, 2022 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the first quarter ended March 31, 2022. ...

Nektar Therapeutics (NASDAQ:NKTR) will implement a cost restructuring plan so that it can focus on its two mid-stage pipeline assets that will result in the loss of 70% of its employees. The company said the plan will extend its cash runway into 1H 2025. After accounting for wind-down an...

Nektar Therapeutics Announces Strategic Reorganization Plan and Corporate Outlook PR Newswire Company focusing on key pipeline programs NKTR-358, NKTR-255 and core research programs Cost restructuring plan results in cash runway into the first half of 2025 ...

Nektar Therapeutics (NASDAQ:NKTR) and its collaborators at the New York Medical College (NYMC) said on Monday that the company’s IL‐15 receptor agonist NKTR-255, in combination with different CAR-T therapies, boosted the activity of Natural Killer (NK) cells in preclinical model...

Nektar and Collaborators Present Preclinical Data on NKTR-255, a Novel IL-15 Receptor Agonist, in combination with CAR Cell Therapies at the 2022 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT™ and CIBMTR® Nektar and Collaborators Present ...

Nektar Therapeutics to Host Webcast Conference Call for Analysts & Investors to Outline New Strategic Plan Nektar Therapeutics to Host Webcast Conference Call for Analysts & Investors to Outline New Strategic Plan PR Newswire SAN FRANCISCO , April...

Regenxbio holds the most powerful gene delivery platform on the planet. The company recently closed a $1.3B deal with AbbVie for the development of RGX314 for wet AMD. RGX202 is the hidden asset, poised to make waves in the coming years. For further details see: Regenxbi...